559 related articles for article (PubMed ID: 25409195)
1. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
[TBL] [Abstract][Full Text] [Related]
2. A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice.
Gorczynski RM; Zhu F; Chen Z; Kos O; Khatri I
Breast Cancer Res Treat; 2017 Apr; 162(2):255-266. PubMed ID: 28160157
[TBL] [Abstract][Full Text] [Related]
3. Characterization of an in vitro model system to explore control of tumor invasion of EMT6 and 4THM breast tumors by CD200:CD200R interactions.
Gorczynski RM; Erin N; Maqbool T; Gorczynski CP; Gorczynski LY
Breast Cancer; 2018 Sep; 25(5):547-559. PubMed ID: 29532324
[TBL] [Abstract][Full Text] [Related]
4. Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response.
Erin N; Podnos A; Tanriover G; Duymuş Ö; Cote E; Khatri I; Gorczynski RM
Oncogene; 2015 Jul; 34(29):3860-70. PubMed ID: 25263452
[TBL] [Abstract][Full Text] [Related]
5. Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.
Gorczynski RM; Chen Z; Khatri I; Podnos A; Yu K
Breast Cancer Res Treat; 2013 Nov; 142(2):271-82. PubMed ID: 24166280
[TBL] [Abstract][Full Text] [Related]
6. Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.
Curry A; Khatri I; Kos O; Zhu F; Gorczynski R
PLoS One; 2017; 12(2):e0171586. PubMed ID: 28234914
[TBL] [Abstract][Full Text] [Related]
7. Serum-derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumor.
Gorczynski RM; Erin N; Zhu F
Cancer Med; 2016 Feb; 5(2):325-36. PubMed ID: 26725371
[TBL] [Abstract][Full Text] [Related]
8. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.
Podnos A; Clark DA; Erin N; Yu K; Gorczynski RM
Breast Cancer Res Treat; 2012 Nov; 136(1):117-27. PubMed ID: 23053647
[TBL] [Abstract][Full Text] [Related]
9. Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice.
Gorczynski RM; Clark DA; Erin N; Khatri I
Breast Cancer Res Treat; 2011 Nov; 130(1):49-60. PubMed ID: 21165772
[TBL] [Abstract][Full Text] [Related]
10. Differential characteristics of heart, liver, and brain metastatic subsets of murine breast carcinoma.
Erin N; Kale S; Tanrıöver G; Köksoy S; Duymuş O; Korcum AF
Breast Cancer Res Treat; 2013 Jun; 139(3):677-89. PubMed ID: 23760857
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
12. CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.
Erin N; Dilmaç S; Curry A; Duymuş Ö; Tanriover G; Prodeus A; Gariepy J; Gorczynski RM
Cancer Immunol Immunother; 2020 Jan; 69(1):103-114. PubMed ID: 31811336
[TBL] [Abstract][Full Text] [Related]
13. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD200R2, anti-IL-9, anti-IL-35, or anti-TGF-β abolishes increased graft survival and Treg induction induced in cromolyn-treated CD200R1KO.CD200tg mice.
Gorczynski R; Yu K; Chen Z
Transplantation; 2014 Jan; 97(1):39-46. PubMed ID: 24142033
[TBL] [Abstract][Full Text] [Related]
15. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor.
Guiducci C; Di Carlo E; Parenza M; Hitt M; Giovarelli M; Musiani P; Colombo MP
J Immunol; 2004 Apr; 172(7):4026-36. PubMed ID: 15034014
[TBL] [Abstract][Full Text] [Related]
16. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
Latimer P; Menchaca M; Snyder RM; Yu W; Gilbert BE; Sanders BG; Kline K
Exp Biol Med (Maywood); 2009 Oct; 234(10):1244-52. PubMed ID: 19657067
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice.
Gorczynski RM; Chen Z; Diao J; Khatri I; Wong K; Yu K; Behnke J
Breast Cancer Res Treat; 2010 Sep; 123(2):405-15. PubMed ID: 19953316
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
19. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
20. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
